Company Monitoring Page for Novartis

latest headlines for company on cafepharma

6 Medtech Acquisitions That Went Horribly Wrong
Medical Devices and Diagnostics Industry
Thu, 07/7/22 - 08:10 pm
Tags:
devices, Medtech, M&A, Medtronic, HeartWare, Second Sight Medical, Pixium Vision, Illumina, PacBio, Novartis, Alcon, Transcend, Organovo, Tarveda Therapeutics, Boston Scientific, Guidant
FDA Has Ways to Go to Keep Pace with 2020/21 Approvals
BioSpace
Wed, 07/6/22 - 11:05 am
Tags:
FDA, drug approvals, Amicus, Bluebird Bio, Bristol Myers Squibb, Eli Lilly, Marinus Pharma, Amylyx, Novartis
Novartis offers $17.7m support in the fight for health equity
Biopharma Reporter
Tue, 07/5/22 - 11:10 am
Tags:
Novartis, physicians, philanthropy, racial disparity
Novartis, staring down tough market for M&A, leans toward $25B Sandoz spinoff: Bloomberg
Fierce Pharma
Fri, 07/1/22 - 09:49 am
Tags:
Novartis, spinoffs, generics, M&A, Sandoz, private equity
Novartis, BeiGene lay out frontline PhIII data for PD-1 drug as second-line PDUFA date looms
Endpoints
Thu, 06/30/22 - 12:11 pm
Tags:
Novartis, BeiGene, FDA, tislelizumab, gastrointestinal cancer
Novartis Reveals Restructure will Cost up to 8,000 Jobs
BioSpace
Tue, 06/28/22 - 06:07 pm
Tags:
Novartis, restructuring, layoffs
Novartis: FDA OKs Tafinlar + Mekinist For Solid Tumors With BRAF V600E Mutation
NASDAQ
Thu, 06/23/22 - 10:57 am
Tags:
Novartis, FDA, Tafinlar+Mekinist, solid tumors, BRAF V600
Novartis pledges $250M in R&D funding for neglected tropical diseases, malaria
Endpoints
Thu, 06/23/22 - 10:37 am
Tags:
Novartis, R&D, tropical diseases, malaria, neglected tropical diseases
Novartis plots Precision attack on sickle cell, paying $75M and putting up $1.4B in biobucks to form in vivo gene editing pact
Fierce Biotech
Wed, 06/22/22 - 10:23 am
Tags:
Novartis, gene editing, Precision Biosciences, sickle cell disease, beta thalassemia
Novartis' recent Gilenya patent win slips away after appeals court reverses its own prior verdict
Fierce Pharma
Tue, 06/21/22 - 11:45 pm
Tags:
Novartis, patents, Gilenya, multiple sclerosis
More drug, fewer jabs: Novartis' Sandoz eyes EMA nod for high-concentration Humira copy
Fierce Pharma
Mon, 06/20/22 - 10:37 am
Tags:
Novartis, Sandoz, AbbVie, Humira, Europe, biosimilars, autoimmune disease, EMA, Hyrimoz
Taking Charge—biotechs already approaching Novartis to partner on 'game changing' CAR-T platform
Fierce Biotech
Tue, 06/14/22 - 11:18 am
Tags:
Novartis, CAR-T, cell therapy, T-Charge
Novartis’ Sandoz Launches Biosimilars Awareness Campaign to Improve Biosimilars Adoption Worldwide
Xtalks
Wed, 06/8/22 - 11:04 pm
Tags:
Novartis, Sandoz, biosimilars, generics
Novartis Combo could be New Standard of Care for Pediatric Glioma Patients
BioSpace
Wed, 06/8/22 - 10:42 am
Tags:
Novartis, Tafinlar, Mekinist, pediatric, clinical trials, glioma, ASCO 2022
In age discrimination suit, US agency sues Novo Nordisk for filling job with younger, less qualified applicant
Fierce Pharma
Wed, 06/8/22 - 10:21 am
Tags:
Novartis, legal, age discrimination, EEOC
Novartis is latest victim of cyberattack, but claims no confidential data compromised — report
Endpoints
Mon, 06/6/22 - 11:49 pm
Tags:
Novartis, cyberattacks, cybersecurity
Novartis resumes remote business in Ukraine after safety protocol review
Endpoints
Thu, 06/2/22 - 07:22 pm
Tags:
Novartis, Ukraine, Russia
Novartis' surprise radiotherapy production halt nearing an end as FDA docs shed light on plant woes
Fierce Pharma
Thu, 06/2/22 - 10:20 am
Tags:
Novartis, radiotherapy, FDA, Lutathera, Pluvicto
Amgen eyes swift move to ph3 for cardiovascular drug olpasiran
Pharmaforum
Wed, 06/1/22 - 09:33 am
Tags:
Amgen, olpasiran, Novartis, clinical trials, cardiovascular disease
Novartis' Sandoz founds new initiative to expand biosimilar use more globally
Endpoints
Tue, 05/31/22 - 11:51 pm
Tags:
Novartis, Sandoz, biosimilars

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.